pipette
ENEnglish

Integrating Multisource Target Evidence with Machine-Learning Potency Prediction for Alzheimer's Disease Drug Discovery

A. Pan, T. Zhai, J. Lee, C. Zheng, D. Kim, L. Shen

Preprint

En palabras de los autores

Alzheimer's disease (AD) target evidence is distributed across biological, chemical, structural, regulatory, and trial-registry sources, complicating reproducible target evaluation and modeling. We developed a traceable data-to-model platform that integrates AGORA-centered evidence through Target Explorer, Drug-Target Lookup, and Model Portfolio workspaces. The resource contains 967 targets, 452,249 compounds, and 1,430,260 measurements. On a curated PIK3CA dataset, target-specific fine-tuning of the Boltz-2 affinity head increased Pearson r from 0.248 to 0.560 and reduced mean absolute error from 0.900 to 0.706 on 469 held-out compounds. Separately, we screened 42 regression models over 50 random splits for ten moderate-sized target datasets; a random forest model for XDH achieved the highest mean R^2 (0.815). The platform connects curated evidence, model-ready datasets, reproducible evaluation, and public results while clearly separating contextual evidence from therapeutic claims and random-split performance from generalization to unseen chemical scaffolds.

Resultado principalLimitación que admiten los autores

Apareció: miércoles, 21 de octubre. bioRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.10.14.759026